The current PE ratio of VNDA can't be determined, as the TTM EPS of -$4.05 is negative. The last PE ratio of Vanda Pharmaceuticals, recorded in December 2023, was 105.5.
The PE ratio of Vanda Pharmaceuticals has averaged 76.68 over the last nine years. Over the past nine years, VNDA's PE ratio was at its highest in the Jun 2018 quarter at 952.5, when the stock price was $19.05 and the EPS was $0.02. The lowest value was in the Mar 2020 quarter, when it reached 4.75 with a price of $10.36 and an EPS of $2.18.
Maximum annual increase: 304.23% in 2020
Maximum annual decrease: -85.53% in 2019
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $8.82 | -$3.74 |
| 2024 | N/A | N/A | $4.79 | -$0.33 |
| 2023 | 105.5 | 57.04% | $4.22 | $0.04 |
| 2022 | 67.18 | 156.9% | $7.39 | $0.11 |
| 2021 | 26.15 | -14.43% | $15.69 | $0.6 |
| 2020 | 30.56 | 304.23% | $13.14 | $0.43 |
| 2019 | 7.56 | -85.53% | $16.41 | $2.17 |
| 2018 | 52.26 | N/A | $26.13 | $0.5 |
| 2017 | N/A | N/A | $15.2 | -$0.35 |
| 2016 | N/A | N/A | $15.95 | -$0.41 |
| 2015 | N/A | N/A | $9.31 | -$0.94 |
| 2014 | 24.69 | N/A | $14.32 | $0.58 |
| 2013 | N/A | N/A | $12.41 | -$0.69 |
| 2012 | N/A | N/A | $3.7 | -$1.01 |
| 2011 | N/A | N/A | $4.76 | -$0.35 |
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | N/A | N/A | $6.91 | -$4.05 |
| Dec 2025 | N/A | N/A | $8.82 | -$3.74 |
| Sep 2025 | N/A | N/A | $4.99 | -$1.43 |
| Jun 2025 | N/A | N/A | $4.72 | -$1.14 |
| Mar 2025 | N/A | N/A | $4.59 | -$0.76 |
| Dec 2024 | N/A | N/A | $4.79 | -$0.33 |
| Sep 2024 | N/A | N/A | $4.69 | -$0.29 |
| Jun 2024 | N/A | N/A | $5.65 | -$0.2 |
| Mar 2024 | N/A | N/A | $4.11 | -$0.09 |
| Dec 2023 | 105.5 | 412.88% | $4.22 | $0.04 |
| Sep 2023 | 20.57 | -15.73% | $4.32 | $0.21 |
| Jun 2023 | 24.41 | 4.27% | $6.59 | $0.27 |
| Mar 2023 | 23.41 | -65.15% | $6.79 | $0.29 |
| Dec 2022 | 67.18 | -11.61% | $7.39 | $0.11 |
| Sep 2022 | 76 | 46.44% | $9.88 | $0.13 |
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BMY Bristol Myers Squibb Co | 16.28 | $118.71B |
| PFE Pfizer Inc | 18.56 | $138.61B |
| NVS Novartis AG | 22.78 | $305.1B |
| JNJ Johnson & Johnson | 30.13 | $633.19B |
| MRK Merck & Co Inc | 36.29 | $319.99B |
| LLY ELI LILLY & Co | 43.06 | $1.14T |
| VNDA Vanda Pharmaceuticals Inc | N/A | $373.44M |
The current price to earnings ratio of VNDA can't be calculated, as its EPS of -$4.05 is negative.
The 5-year average PE ratio for VNDA stock is 45.7.
The highest quarterly PE ratio in the last nine years has been 952.5 and it was in the Jun 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.